1
|
Bardellini E, Amadori F, Garo ML, Majorana A, Conti G. Is there any correlation between otitis media and dental malocclusion in children? A systematic review. Eur Arch Paediatr Dent 2023:10.1007/s40368-023-00807-0. [PMID: 37338742 PMCID: PMC10382365 DOI: 10.1007/s40368-023-00807-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2022] [Accepted: 05/15/2023] [Indexed: 06/21/2023]
Abstract
PURPOSE This study aims to evaluate whether there is a correlation between otitis and dental malocclusions. METHODS Electronic databases were searched for observational studies published until July 2021 without language or time restrictions. PROSPERO CRD42021270760. Observational studies on children with and without OM and/or malocclusion were included. After removing duplicates and excluding not-eligible articles, two reviewers screened relevant articles independently. Two reviewers independently extracted data and assessed data quality and validity through the Newcastle-Ottawa Scale (NOS) quality assessment tool for non-randomized studies. RESULTS Five studies met the selection inclusion criteria and were included in the studies for a total of 499 patients. Three studies investigated the relationship between malocclusion and otitis media, while the remaining two studies analyzed the inverse relationship and one of them considered eustachian tube dysfunction as a proxy of OM. An association between malocclusion and otitis media and vice versa emerged, although with relevant limitations. CONCLUSION There is some evidence that there is an association between otitis and malocclusion; however, it is not yet possible to establish a definitive correlation.
Collapse
Affiliation(s)
- E Bardellini
- Department of Medical and Surgery Specialties, Radiological Sciences and Public Health, School of Pediatric Dentistry, University of Brescia, Dental Clinic, P.le Spedali Civili N.1, 25133, Brescia, Italy.
| | - F Amadori
- Department of Medical and Surgery Specialties, Radiological Sciences and Public Health, School of Pediatric Dentistry, University of Brescia, Dental Clinic, P.le Spedali Civili N.1, 25133, Brescia, Italy
| | - M L Garo
- Department of Medical and Surgery Specialties, Radiological Sciences and Public Health, School of Pediatric Dentistry, University of Brescia, Dental Clinic, P.le Spedali Civili N.1, 25133, Brescia, Italy
| | - A Majorana
- Department of Medical and Surgery Specialties, Radiological Sciences and Public Health, School of Pediatric Dentistry, University of Brescia, Dental Clinic, P.le Spedali Civili N.1, 25133, Brescia, Italy
| | - G Conti
- University of Insubria, Varese, Italy
| |
Collapse
|
2
|
Tomisti L, Angelotti F, Lenzi M, Amadori F, Sarteschi G, Porcu A, Capria AL, Bertacca G, Lombardi S, Bianchini G, Vincenti A, Cesta N. Efficacy of Convalescent Plasma to Treat Long-Standing COVID-19 in Patients with B-Cell Depletion. Life (Basel) 2023; 13:1266. [PMID: 37374049 DOI: 10.3390/life13061266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2023] [Revised: 04/21/2023] [Accepted: 05/24/2023] [Indexed: 06/29/2023] Open
Abstract
The use of antivirals, corticosteroids, and IL-6 inhibitors has been recommended by the WHO to treat COVID-19. CP has also been considered for severe and critical cases. Clinical trials on CP have shown contradictory results, but an increasing number of patients, including immunocompromised ones, have shown benefits from this treatment. We reported two clinical cases of patients with prolonged COVID-19 infection and B-cell depletion who showed rapid clinical and virological recovery after the administration of CP. The first patient in this study was a 73-year-old female with a history of follicular non-Hodgkin lymphoma previously treated with bendamustine followed by maintenance therapy with rituximab. The second patient was a 68-year-old male with chronic obstructive pulmonary disease, bipolar disorder, alcoholic liver disease, and a history of mantellar non-Hodgkin lymphoma treated with rituximab and radiotherapy. After the administration of CP, both patients showed a resolution of symptoms, improvement of their clinical conditions, and a negative result of the nasopharyngeal swab test. The administration of CP might be effective in resolving symptoms and improving clinical and virological outcomes in patients with B-cell depletion and prolonged SARS-CoV2 infections.
Collapse
Affiliation(s)
- Luca Tomisti
- ASL Toscana Nord-Ovest, Internal Medicine Department, Nuovo Ospedale Apuano, 54100 Massa, Italy
| | - Francesca Angelotti
- ASL Toscana Nord-Ovest, Internal Medicine Department, Nuovo Ospedale Apuano, 54100 Massa, Italy
| | - Mirco Lenzi
- ASL Toscana Nord-Ovest, Infectious Diseases Department, Nuovo Ospedale Apuano, 54100 Massa, Italy
| | - Francesco Amadori
- ASL Toscana Nord-Ovest, Infectious Diseases Department, Nuovo Ospedale Apuano, 54100 Massa, Italy
| | - Giovanni Sarteschi
- ASL Toscana Nord-Ovest, Infectious Diseases Department, Nuovo Ospedale Apuano, 54100 Massa, Italy
| | - Anna Porcu
- ASL Toscana Nord-Ovest, Pneumology Department, Nuovo Ospedale Apuano, 54100 Massa, Italy
| | - Anna-Lisa Capria
- UOC Virologia, Dipartimento di Medicina di Laboratorio, AOUP Azienda Ospedaliero Universitaria Pisana, 56100 Pisa, Italy
| | - Gloria Bertacca
- ASL Toscana Nord-Ovest, SSD Clinical Chemistry Analyses and Molecular Biology, Nuovo Ospedale Apuano, 54100 Massa, Italy
| | - Stefania Lombardi
- ASL Toscana Nord-Ovest, SSD Clinical Chemistry Analyses and Molecular Biology, Nuovo Ospedale Apuano, 54100 Massa, Italy
| | - Guido Bianchini
- ASL Toscana Nord-Ovest, Internal Medicine Department, Nuovo Ospedale Apuano, 54100 Massa, Italy
| | - Antonella Vincenti
- ASL Toscana Nord-Ovest, Infectious Diseases Department, Nuovo Ospedale Apuano, 54100 Massa, Italy
| | - Novella Cesta
- ASL Toscana Nord-Ovest, Infectious Diseases Department, Nuovo Ospedale Apuano, 54100 Massa, Italy
| |
Collapse
|
3
|
Manciulli T, Spinicci M, Rossetti B, Antonello RM, Lagi F, Barbiero A, Chechi F, Formica G, Francalanci E, Alesi M, Gaggioli S, Modi G, Modica S, Paggi R, Costa C, Morea A, Paglicci L, Rancan I, Amadori F, Tamborrino A, Tilli M, Bandini G, Pignone AM, Valoriani B, Montagnani F, Tumbarello M, Blanc P, Di Pietro M, Galli L, Aquilini D, Vincenti A, Sani S, Nencioni C, Luchi S, Tacconi D, Zammarchi L, Bartoloni A. Safety and Efficacy of Outpatient Treatments for COVID-19: Real-Life Data from a Regionwide Cohort of High-Risk Patients in Tuscany, Italy (the FEDERATE Cohort). Viruses 2023; 15:v15020438. [PMID: 36851654 PMCID: PMC9967010 DOI: 10.3390/v15020438] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2022] [Revised: 01/28/2023] [Accepted: 01/28/2023] [Indexed: 02/09/2023] Open
Abstract
Early COVID-19 treatments can prevent progression to severe disease. However, real-life data are still limited, and studies are warranted to monitor the efficacy and tolerability of these drugs. We retrospectively enrolled outpatients receiving early treatment for COVID-19 in 11 infectious diseases units in the Tuscany region of Italy between 1 January and 31 March 2022, when Omicron sublineages BA.1 and BA.2 were circulating. Eligible COVID-19 patients were treated with sotrovimab (SOT), remdesivir (RMD), nirmatrelvir/ritonavir (NRM/r), or molnupiravir (MOL). We gathered demographic and clinical features, 28-day outcomes (hospitalization or death), and drugs tolerability. A total of 781 patients (median age 69.9, 66% boosted for SARS-CoV-2) met the inclusion criteria, of whom 314 were treated with SOT (40.2%), 205 with MOL (26.3%), 142 with RMD (18.2%), and 120 with NRM/r (15.4%). Overall, 28-day hospitalization and death occurred in 18/781 (2.3%) and 3/781 (0.3%), respectively. Multivariable Cox regression showed that patients receiving SOT had a reduced risk of meeting the composite outcome (28-day hospitalization and/or death) in comparison to the RMD cohort, while no significant differences were evidenced for the MOL and NRM/r groups in comparison to the RMD group. Other predictors of negative outcomes included cancer, chronic kidney disease, and a time between symptoms onset and treatment administration > 3 days. All treatments showed good safety and tolerability, with only eight patients (1%) whose treatment was interrupted due to intolerance. In the first Italian multicenter study presenting real-life data on COVID-19 early treatments, all regimens demonstrated good safety and efficacy. SOT showed a reduced risk of progression versus RMD. No significant differences of outcome were observed in preventing 28-day hospitalization and death among patients treated with RMD, MOL, and NRM/r.
Collapse
Affiliation(s)
- Tommaso Manciulli
- Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze, 50121 Firenze, Italy
| | - Michele Spinicci
- Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze, 50121 Firenze, Italy
- SOD Malattie Infettive e Tropicali, Azienda Ospedaliero-Universitaria Careggi, 50134 Firenze, Italy
| | - Barbara Rossetti
- UOC Malattie Infettive, Ospedale Misericordia, 58100 Grosseto, Italy
| | - Roberta Maria Antonello
- Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze, 50121 Firenze, Italy
| | - Filippo Lagi
- Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze, 50121 Firenze, Italy
- SOD Malattie Infettive e Tropicali, Azienda Ospedaliero-Universitaria Careggi, 50134 Firenze, Italy
| | - Anna Barbiero
- Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze, 50121 Firenze, Italy
| | - Flavia Chechi
- Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze, 50121 Firenze, Italy
- SOC Malattie Infettive, Ospedale San Jacopo, 51100 Pistoia, Italy
| | - Giuseppe Formica
- Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze, 50121 Firenze, Italy
| | - Emanuela Francalanci
- Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze, 50121 Firenze, Italy
- UO Malattie Infettive, Ospedale Santo Stefano, 59100 Prato, Italy
| | - Mirco Alesi
- Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze, 50121 Firenze, Italy
- UO Malattie Infettive, Ospedale Santo Stefano, 59100 Prato, Italy
| | - Samuele Gaggioli
- Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze, 50121 Firenze, Italy
| | - Giulia Modi
- Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze, 50121 Firenze, Italy
- UO Malattie Infettive, Ospedale Santa Maria Annunziata, 50012 Firenze, Italy
| | - Sara Modica
- SOC Malattie Infettive ed Epatologia, Ospedale San Luca, 55100 Lucca, Italy
| | - Riccardo Paggi
- Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze, 50121 Firenze, Italy
- SOC Malattie Infettive, Ospedale San Jacopo, 51100 Pistoia, Italy
| | - Cecilia Costa
- UO Malattie Infettive, Ospedale Santa Maria Annunziata, 50012 Firenze, Italy
| | - Alessandra Morea
- UO Malattie Infettive, Ospedali Riuniti di Livorno, 57124 Livorno, Italy
| | | | - Ilaria Rancan
- Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze, 50121 Firenze, Italy
- Dipartimento di Biotecnologie Mediche, Università degli Studi di Siena, 53100 Siena, Italy
| | | | - Agnese Tamborrino
- Dipartimento Scienze della Salute, Università degli Studi di Firenze, 50139 Firenze, Italy
| | - Marta Tilli
- Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze, 50121 Firenze, Italy
- UO Malattie Infettive, Ospedale Santa Maria Annunziata, 50012 Firenze, Italy
| | - Giulia Bandini
- Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze, 50121 Firenze, Italy
| | - Alberto Moggi Pignone
- Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze, 50121 Firenze, Italy
| | | | - Francesca Montagnani
- Dipartimento di Biotecnologie Mediche, Università degli Studi di Siena, 53100 Siena, Italy
- UOC Malattie Infettive e Tropicali, Azienda Ospedaliero Universitaria Senese, 53100 Siena, Italy
| | - Mario Tumbarello
- Dipartimento di Biotecnologie Mediche, Università degli Studi di Siena, 53100 Siena, Italy
- UOC Malattie Infettive e Tropicali, Azienda Ospedaliero Universitaria Senese, 53100 Siena, Italy
| | - Pierluigi Blanc
- SOC Malattie Infettive, Ospedale San Jacopo, 51100 Pistoia, Italy
| | - Massimo Di Pietro
- UO Malattie Infettive, Ospedale Santa Maria Annunziata, 50012 Firenze, Italy
| | - Luisa Galli
- Dipartimento Scienze della Salute, Università degli Studi di Firenze, 50139 Firenze, Italy
- UO Malattie Infettive, Azienda Ospedaliero-Universitaria “Meyer”, 50139 Firenze, Italy
| | | | | | - Spartaco Sani
- UO Malattie Infettive, Ospedali Riuniti di Livorno, 57124 Livorno, Italy
| | - Cesira Nencioni
- UOC Malattie Infettive, Ospedale Misericordia, 58100 Grosseto, Italy
| | - Sauro Luchi
- SOC Malattie Infettive ed Epatologia, Ospedale San Luca, 55100 Lucca, Italy
| | - Danilo Tacconi
- UO Malattie Infettive, Ospedale San Donato, 52100 Arezzo, Italy
| | - Lorenzo Zammarchi
- Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze, 50121 Firenze, Italy
- SOD Malattie Infettive e Tropicali, Azienda Ospedaliero-Universitaria Careggi, 50134 Firenze, Italy
| | - Alessandro Bartoloni
- Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze, 50121 Firenze, Italy
- SOD Malattie Infettive e Tropicali, Azienda Ospedaliero-Universitaria Careggi, 50134 Firenze, Italy
- Correspondence:
| |
Collapse
|
4
|
Bardellini E, Bondioni MP, Amadori F, Veneri F, Lougaris V, Meini A, Plebani A, Majorana A. Non-specific oral and cutaneous manifestations of Coronavirus Disease 2019 in children. Med Oral Patol Oral Cir Bucal 2021; 26:e549-e553. [PMID: 33772567 PMCID: PMC8412440 DOI: 10.4317/medoral.24461] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2020] [Accepted: 03/16/2021] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Coronavirus Disease 2019 (COVID-19) seems to affect children only marginally, as a result, there is less knowledge of its manifestations in childhood. The purpose of this retrospective cross-sectional study was to investigate the oral and cutaneous manifestations in children affected by COVID-19. MATERIAL AND METHODS All the medical records of children with COVID-19 admitted to the Pediatric Clinic- ASST Spedali Civili of Brescia from March to April 2020 were reviewed. The following data were recorded: age, temperature, clinical presentation, oral mucosa lesions, taste alteration and cutaneous lesions. RESULTS The medical records of twenty-seven pediatric patients (mean age 4,2 years + 1,7) were analyzed. The clinical presentation of the disease mainly included elevated body temperature and cough. The following oral lesions were recorded: oral pseudomembranous candidiasis (7.4 %), geographic tongue (3.7%), coated tongue (7.4 %) and hyperaemic pharynx (37 %). Taste alteration was reported by 3 patients. Six patients presented cutaneous flat papular lesions. CONCLUSIONS As for our paediatric sample, COVID-19 resulted to be associated with non-specific oral and cutaneous manifestations.
Collapse
Affiliation(s)
- E Bardellini
- Dental Clinic p.le Spedali Civili n.1 25133 Brescia, Italy
| | | | | | | | | | | | | | | |
Collapse
|
5
|
Veneri F, Bardellini E, Amadori F, Gobbi E, Bulgari D, Mortellaro C, Greco Lucchina A, Majorana A. Taste sensitivity in healthy adults: gustatory test validation and observational study. J BIOL REG HOMEOS AG 2021; 35:173-180. [PMID: 34281314 DOI: 10.23812/21-2supp1-17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Gustatory sensitivity has important biological functions and taste disorders are generally difficult to diagnose and treat. The aim of this study was to investigate taste sensitivity on a sample of adult healthy patients through the validation and administration of a gustatory test, to describe a possible baseline of reference. A gustatory test was performed following a standardized protocol, using primary flavors solutions at 4 known increasing concentrations for a total of 16 sapid solutions. Taste sensitivity was investigated considering (a) the threshold of the flavor identification and (b) the intensity of stimulus perception. Seventy-one healthy patients were included in the study. Reliability measures were evaluated, supporting the validity of the test itself. Sweet, bitter, and salty flavors could be identified within the first concentration, sour flavor was detected within the second concentration in the majority of cases (p<0.05). Sour flavor showed the lowest value of perceived intensity for the less concentrated solution, sweet flavor showed the highest value. Regarding the most concentrated solution, bitter flavor showed the highest intensity value, while sour remained the lowest one. Both gender-based and age-based differences regarding threshold and intensity of perception were not statistically significant. However mean threshold averagely increased along with age. Within its limitations, this study validates a useful, easy-to-use tool for assessing taste function and it provides a possible baseline for perception of primary flavors in a healthy adult population, which can be used as a reference for future studies considering specific cohorts of patients.
Collapse
Affiliation(s)
- F Veneri
- Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Dental Clinic, Department of Oral Medicine, University of Brescia, Brescia, Italy
| | - E Bardellini
- Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Dental Clinic, Department of Oral Medicine, University of Brescia, Brescia, Italy
| | - F Amadori
- Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Dental Clinic, Department of Oral Medicine, University of Brescia, Brescia, Italy
| | - E Gobbi
- Agrifood and Environmental Microbiology Platform (PiMiAA-AgroFood Lab), Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
| | - D Bulgari
- Agrifood and Environmental Microbiology Platform (PiMiAA-AgroFood Lab), Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
| | - C Mortellaro
- Saint Camillus International University of Health and Medical Science, Rome, Italy
| | - A Greco Lucchina
- Saint Camillus International University of Health and Medical Science, Rome, Italy
| | - A Majorana
- Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Dental Clinic, Department of Oral Medicine, University of Brescia, Brescia, Italy
| |
Collapse
|
6
|
Veneri F, Bardellini E, Amadori F, Conti G, Majorana A. Efficacy of ozonized water for the treatment of erosive oral lichen planus: a randomized controlled study. Med Oral Patol Oral Cir Bucal 2020; 25:e675-e682. [PMID: 32683383 PMCID: PMC7473429 DOI: 10.4317/medoral.23693] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2020] [Accepted: 06/14/2020] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND Management of erosive Oral Lichen Planus (eOLP) is challenging. Currently, topical corticosteroids are widely used as first-line therapy, but they might be associated with side-effects and incomplete clinical response. Among non-pharmacological strategies, ozone at low medical concentration has proven to induce a mild activation of protective anti-oxidant pathways, thus exerting therapeutic effects in many inflammatory diseases. The aim of this randomized controlled study was to investigate the effectiveness of ozonized water in association with conventional topical corticosteroids for the treatment of eOLP. MATERIAL AND METHODS Fifty-one patients were included in the study and randomized into 2 groups: study group (n=26) included patients receiving ozonized water treatment; control group (n=25) included patients receiving placebo treatment (i.e. double-distilled water). Treatment protocol consisted of 1-minute oral rinses, repeated for 4 times, twice a week for 4 weeks. All patients received conventional corticosteroid topical therapy (betamethasone soluble tablets, 2 rinses/day for 4 weeks). Assessment of size of lesions, sign and pain scores was performed before treatment, after 2 weeks of treatment (T1) and at the end of 4-week treatment (T2). Efficacy Index (EI) of treatment, candidiasis and relapse rates were also recorded. RESULTS All patients experienced significant improvement of sign and pain scores with a higher rate of improvement in ozone-treated group (T1 improvement rates: Thongprasom 92.2% vs 28%; VAS pain 76.9% vs 32%; p<0.05). Pain and size reduction were significantly higher in ozone-treated group both at T1 and T2 (p<0.05). Ozone-treated group showed a higher EI at every time point (T0-T2: 72.77% vs 37.66%, p<0.01). Candidiasis (32% vs 11.5%) and relapse (40% vs 34.6%) rates were higher in control group, however the differences were not statistically significant. CONCLUSIONS Within the limitations of this study, ozonized water seems to be effective as an adjunct therapy, in combination with topical corticosteroids, for the treatment of eOLP.
Collapse
Affiliation(s)
| | - E Bardellini
- Dental Clinic, p.le Spedali Civili n.1 25133 Brescia
| | | | | | | |
Collapse
|
7
|
Amadori F, Terracciano E, Gennaio I, Mita V, Gargano D, Zaratti L, Franco E, Arigliani R. Opinions and attitudes of Italian healthcare workers towards recommended but not compulsory rotavirus vaccination. Hum Vaccin Immunother 2020; 17:497-502. [PMID: 32614732 PMCID: PMC7899670 DOI: 10.1080/21645515.2020.1776546] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
Rotaviruses (RVs) are a leading cause of viral gastroenteritis among children younger than 5. The incidence of RV disease can be reduced through the widespread use of vaccination, but coverage is low in many countries, including Italy. This fact reflects the poor consideration given to the RV vaccine, both by the population and by healthcare workers. Peoples’ opinions are strictly dependent on the attitude of doctors and nurses. The aim of this work is the evaluation of healthcare workers’ knowledge, attitudes and opinions regarding RV vaccination. The results of two surveys were compared; the first was carried out in 2017, soon after the Italian National Immunization Plan introduced the recommendation for the RV vaccine. The second was performed at the end of 2018, approximately 1 year after the adoption of a Law that introduced new compulsory vaccinations, not including the RV vaccine. In 2017, 182 questionnaires were collected, and 111 in 2018. An increase was observed in the percentage of participants who reported recommending the RV vaccine and a significant increase was found in the coverage the participants claimed to reach. Education of healthcare workers after the introduction of compulsory vaccination may prompt them to actively offer also recommended vaccines.
Collapse
Affiliation(s)
- F Amadori
- Specialization School for Hygiene and Preventive Medicine, University of Rome Tor Vergata , Rome, Italy
| | - E Terracciano
- Specialization School for Hygiene and Preventive Medicine, University of Rome Tor Vergata , Rome, Italy
| | - I Gennaio
- Department of Biomedicine and Prevention, University of Rome Tor Vergata , Rome, Italy
| | - V Mita
- Department of Biomedicine and Prevention, University of Rome Tor Vergata , Rome, Italy
| | - D Gargano
- Nursing Service, Bambino Gesù Children's Hospital, Rome, Italy
| | - L Zaratti
- Department of Biomedicine and Prevention, University of Rome Tor Vergata , Rome, Italy
| | - E Franco
- Department of Biomedicine and Prevention, University of Rome Tor Vergata , Rome, Italy
| | - R Arigliani
- School of Counselling, Italian Medical Research Institute , Benevento, Italy
| |
Collapse
|
8
|
Bardellini E, Veneri F, Amadori F, Conti G, Majorana A. Photobiomodulation therapy for the management of recurrent aphthous stomatitis in children: clinical effectiveness and parental satisfaction. Med Oral Patol Oral Cir Bucal 2020; 25:e549-e553. [PMID: 32388522 PMCID: PMC7338059 DOI: 10.4317/medoral.23573] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2019] [Accepted: 02/10/2020] [Indexed: 01/26/2023] Open
Abstract
Background This study aims to evaluate the effectiveness of the photobiomodulation therapy (PBMT) in the treatment of minor recurrent aphthous stomatitis (MiRAS) in children, in terms of pain relief, lesion size reduction and the parental satisfaction of the therapy.
Material and Methods This randomized controlled study was carried out on 60 children with clinical diagnosis of MiRAS. Patients were randomized into two groups: group A receiving laser therapy and group B receiving sham therapy (placebo). Laser therapy (diode laser, λ: 645 nm) was administered on day 1 (T0) for three consecutive days. Patients were evaluated also on day 4 (T1), on day 7 (T2) and on day 10 (T3). Oral aphthous lesions size was assessed through a periodontal probe to measure the diameter length (mm); pain was evaluated through the Visual Analogue Scale (VAS); parental satisfaction was assessed through a questionnaire.
Results The difference in the reduction of ulcers diameters between the two groups resulted statistically significant at T1 and at T2 (p<0.05). A statistically significant difference in pain reduction between two groups was found at T1 (p<0.05). No statistically significant difference between the two groups of parents was found as concerns the parental acceptance of the procedure and the discomfort for the need of multiple appointments.
Conclusions PBMT is to be considered effective in the treatment of MiRAS in children and well- accepted by the parents of the children themselves. Key words:Ulcers, children, lasers
Collapse
Affiliation(s)
- E Bardellini
- Dental Clinic, p.le Spedali Civili n.1 25133 Brescia
| | | | | | | | | |
Collapse
|
9
|
Tumbarello M, Trecarichi EM, Corona A, De Rosa FG, Bassetti M, Mussini C, Menichetti F, Viscoli C, Campoli C, Venditti M, De Gasperi A, Mularoni A, Tascini C, Parruti G, Pallotto C, Sica S, Concia E, Cultrera R, De Pascale G, Capone A, Antinori S, Corcione S, Righi E, Losito AR, Digaetano M, Amadori F, Giacobbe DR, Ceccarelli G, Mazza E, Raffaelli F, Spanu T, Cauda R, Viale P. Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae. Clin Infect Dis 2020; 68:355-364. [PMID: 29893802 DOI: 10.1093/cid/ciy492] [Citation(s) in RCA: 232] [Impact Index Per Article: 58.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2018] [Accepted: 06/06/2018] [Indexed: 12/21/2022] Open
Abstract
Background Ceftazidime-avibactam (CAZ-AVI) has been approved in Europe for the treatment of complicated intra-abdominal and urinary tract infections, as well as hospital-acquired pneumonia, and for gram-negative infections with limited treatment options. CAZ-AVI displays in vitro activity against Klebsiella pneumoniae carbapenemase (KPC) enzyme producers, but clinical trial data on its efficacy in this setting are lacking. Methods We retrospectively reviewed 138 cases of infections caused by KPC-producing K. pneumoniae (KPC-Kp) in adults who received CAZ-AVI in compassionate-use programs in Italy. Case features and outcomes were analyzed, and survival was then specifically explored in the large subcohort whose infections were bacteremic. Results The 138 patients started CAZ-AVI salvage therapy after a first-line treatment (median, 7 days) with other antimicrobials. CAZ-AVI was administered with at least 1 other active antibiotic in 109 (78.9%) cases. Thirty days after infection onset, 47 (34.1%) of the 138 patients had died. Thirty-day mortality among the 104 patients with bacteremic KPC-Kp infections was significantly lower than that of a matched cohort whose KPC-Kp bacteremia had been treated with drugs other than CAZ-AVI (36.5% vs 55.8%, P = .005). Multivariate analysis of the 208 cases of KPC-Kp bacteremia identified septic shock, neutropenia, Charlson comorbidity index ≥3, and recent mechanical ventilation as independent predictors of mortality, whereas receipt of CAZ-AVI was the sole independent predictor of survival. Conclusions CAZ-AVI appears to be a promising drug for treatment of severe KPC-Kp infections, especially those involving bacteremia.
Collapse
Affiliation(s)
- Mario Tumbarello
- Institute of Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli - Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)-Università Cattolica del Sacro Cuore, Rome
| | - Enrico Maria Trecarichi
- Institute of Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli - Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)-Università Cattolica del Sacro Cuore, Rome
| | - Alberto Corona
- Intensive Care Unit Department of Emergency, Luigi Sacco Hospital-Azienda Socio Sanitaria Territoriale (ASST)-Fatebenefratelli Sacco, University of Milan
| | | | - Matteo Bassetti
- Infectious Disease Division, Santa Maria Misericordia University Hospital, Udine
| | - Cristina Mussini
- Clinica delle Malattie Infettive, Università di Modena e Reggio Emilia
| | | | - Claudio Viscoli
- Infectious Diseases Division, Università di Genova e Ospedale Policlinico San Martino IRCCS per l'oncologia e le neuroscienze, Genoa
| | - Caterina Campoli
- Infectious Diseases Unit, Department of Medical and Clinical Sciences, S. Orsola-Malpighi Hospital, Alma Mater Studiorum University of Bologna
| | - Mario Venditti
- Dipartimento di Salute Pubblica e Malattie Infettive, Policlinico Umberto I Università 'Sapienza', Rome
| | | | - Alessandra Mularoni
- Infectious Diseases Istituto mediterraneo per i trapianti e terapie ad alta specializzazione-IRCCS Palermo
| | - Carlo Tascini
- Prima divisione di Malattie Infettive, Ospedale Cotugno, Azienda Ospedaliera dei Colli, Napoli
| | - Giustino Parruti
- Unità Operativa Complessa Malattie Infettive, Azienda Unità Sanitaria Locale Pescara
| | - Carlo Pallotto
- Infectious Diseases Section, Department of Medicine, University of Perugia
| | - Simona Sica
- Institute of Hematology, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli, Rome
| | - Ercole Concia
- Malattie Infettive, Ospedale Universitario di Verona
| | - Rosario Cultrera
- Malattie Infettive, Dipartimento di Scienze Mediche, Università degli Studi di Ferrara
| | - Gennaro De Pascale
- Department of Intensive Care and Anaesthesiology, Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome
| | - Alessandro Capone
- Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani IRCCS Rome
| | - Spinello Antinori
- Department of Clinical and Biomedical Sciences "L. Sacco," University of Milan
| | | | - Elda Righi
- Infectious Disease Division, Santa Maria Misericordia University Hospital, Udine
| | - Angela Raffaella Losito
- Institute of Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli - Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)-Università Cattolica del Sacro Cuore, Rome
| | | | | | - Daniele Roberto Giacobbe
- Infectious Diseases Division, Università di Genova e Ospedale Policlinico San Martino IRCCS per l'oncologia e le neuroscienze, Genoa
| | - Giancarlo Ceccarelli
- Dipartimento di Salute Pubblica e Malattie Infettive, Policlinico Umberto I Università 'Sapienza', Rome
| | - Ernestina Mazza
- Anestesia Rianimazione 2-ASST ospedale Niguarda Ca Granda, Milan
| | - Francesca Raffaelli
- Institute of Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli - Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)-Università Cattolica del Sacro Cuore, Rome
| | - Teresa Spanu
- Institute of Microbiology, Fondazione Policlinico Universitario A. Gemelli IRCCS-Università Cattolica del Sacro Cuore, Rome, Italy
| | - Roberto Cauda
- Institute of Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli - Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)-Università Cattolica del Sacro Cuore, Rome
| | - Pierluigi Viale
- Infectious Diseases Unit, Department of Medical and Clinical Sciences, S. Orsola-Malpighi Hospital, Alma Mater Studiorum University of Bologna
| |
Collapse
|
10
|
Bardellini E, Amadori F, Conti G, Majorana A. Efficacy of the photobiomodulation therapy in the treatment of the burning mouth syndrome. Med Oral Patol Oral Cir Bucal 2019; 24:e787-e791. [PMID: 31655841 PMCID: PMC6901136 DOI: 10.4317/medoral.23143] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2019] [Accepted: 07/07/2019] [Indexed: 12/16/2022] Open
Abstract
Background This study aims to evaluate the efficacy of the photobiomodulation therapy (PBMT) - in terms of pain and of quality of life- in patients affected by burning mouth syndrome (BMS).
Material and Methods This study was designed as a randomised double-blinded prospective study. Patients diagnosed with BMS in the period from June 2015 to June 2018 were recruited. The patients were randomised into two groups and each received treatment once a week for ten weeks: group A received laser therapy (K Laser Cube 3®) while group B was given sham therapy (placebo). Pain was evaluated through the Visual Analogue Scale (VAS) and quality of life was assessed with the short form of the Oral Health Impact Profile (OHIP-14). Assessment was done at baseline and after every therapy session. The researchers were blind to the randomised allocations.
Results A total of 85 patients were analysed. Group A (laser treatment) was composed of 43 patients while group B (sham therapy) of 42 patients. Patients treated with PBMT showed a significant decrease in symptoms (p=0.0008) and improved quality of life related to oral health (p=0.0002). Conclusions PBMT has demonstrated to have a positive effect in relieving BMS symptoms and in improving a patient’s overall quality of life. Key words:Burning mouth syndrome, oral cavity, lasers, life quality.
Collapse
Affiliation(s)
- E Bardellini
- Dental Clinic, p.le Spedali Civili n.1 25133 Brescia
| | | | | | | |
Collapse
|
11
|
Russo A, Bassetti M, Ceccarelli G, Carannante N, Losito AR, Bartoletti M, Corcione S, Granata G, Santoro A, Giacobbe DR, Peghin M, Vena A, Amadori F, Segala FV, Giannella M, Di Caprio G, Menichetti F, Del Bono V, Mussini C, Petrosillo N, De Rosa FG, Viale P, Tumbarello M, Tascini C, Viscoli C, Venditti M. Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: Clinical features, therapy and outcome from a multicenter study. J Infect 2019; 79:130-138. [PMID: 31145911 DOI: 10.1016/j.jinf.2019.05.017] [Citation(s) in RCA: 60] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2018] [Revised: 05/23/2019] [Accepted: 05/24/2019] [Indexed: 11/18/2022]
Abstract
OBJECTIVES bloodstream infections (BSI) due to multidrug-resistant (MDR) Acinetobacter baumannii (AB) have been increasingly observed among hospitalized patients. METHODS prospective, observational study conducted among 12 large tertiary-care hospitals, across 7 Italian regions. From June 2017 to June 2018 all consecutive hospitalized patients with bacteremia due to MDR-AB were included and analyzed in the study. RESULTS During the study period 281 episodes of BSI due to MDR-AB were observed: 98 (34.8%) episodes were classified as primary bacteremias, and 183 (65.2%) as secondary bacteremias; 177 (62.9%) of them were associated with septic shock. Overall, 14-day mortality was observed in 172 (61.2%) patients, while 30-day mortality in 207 (73.6%) patients. On multivariate analysis, previous surgery, continuous renal replacement therapy, inadequate source control of infection, and pneumonia were independently associated with higher risk of septic shock. Instead, septic shock and Charlson Comorbidity Index >3 were associated with 14-day mortality, while adequate source control of infection and combination therapy with survival. Finally, septic shock, previous surgery, and aminoglycoside-containing regimen were associated with 30-day mortality, while colistin-containing regimen with survival. CONCLUSIONS BSI caused by MDR-AB represents a difficult challenge for physicians, considering the high rates of septic shock and mortality associated with this infection.
Collapse
Affiliation(s)
- Alessandro Russo
- Infectious Diseases Clinic, Department of Medicine, University of Udine and Azienda Sanitaria Universitaria Integrata Presidio Ospedaliero Universitario Santa Maria della Misericordia, Udine, Italy
| | - Matteo Bassetti
- Infectious Diseases Clinic, Department of Medicine, University of Udine and Azienda Sanitaria Universitaria Integrata Presidio Ospedaliero Universitario Santa Maria della Misericordia, Udine, Italy
| | - Giancarlo Ceccarelli
- Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I, Viale dell'Università 37, 00161 Rome, Italy
| | - Novella Carannante
- First division of Infectious Diseases, Cotugno Hospital, AORN dei Colli, Naples, Italy
| | - Angela Raffaella Losito
- Institute of Infectious Diseases, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy
| | - Michele Bartoletti
- Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
| | - Silvia Corcione
- Department of Medical Sciences, University of Turin, Infectious Diseases, City of Health and Sciences, Turin, Italy
| | - Guido Granata
- Clinical and Research Department for Infectious Diseases, Unit Systemic and Immunedepression-Associated Infections, National Institute for Infectious Diseases L. Spallanzani, Rome, Italy
| | | | - Daniele Roberto Giacobbe
- Infectious Diseases Unit, Ospedale Policlinico San Martino - IRCCS per l'Oncologia, Italy; Department of Health Sciences, University of Genoa, Genoa, Italy
| | - Maddalena Peghin
- Infectious Diseases Clinic, Department of Medicine, University of Udine and Azienda Sanitaria Universitaria Integrata Presidio Ospedaliero Universitario Santa Maria della Misericordia, Udine, Italy
| | - Antonio Vena
- Infectious Diseases Clinic, Department of Medicine, University of Udine and Azienda Sanitaria Universitaria Integrata Presidio Ospedaliero Universitario Santa Maria della Misericordia, Udine, Italy
| | - Francesco Amadori
- Infectious Diseases Clinic, Nuovo Santa Chiara University Hospital, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
| | - Francesco Vladimiro Segala
- Department of Medical Sciences, University of Turin, Infectious Diseases, City of Health and Sciences, Turin, Italy
| | - Maddalena Giannella
- Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
| | - Giovanni Di Caprio
- First division of Infectious Diseases, Cotugno Hospital, AORN dei Colli, Naples, Italy
| | - Francesco Menichetti
- Infectious Diseases Clinic, Nuovo Santa Chiara University Hospital, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
| | - Valerio Del Bono
- Infectious Diseases Unit, Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy
| | - Cristina Mussini
- Clinic of Infectious Disease, University Hospital, Modena, Italy
| | - Nicola Petrosillo
- Clinical and Research Department for Infectious Diseases, Unit Systemic and Immunedepression-Associated Infections, National Institute for Infectious Diseases L. Spallanzani, Rome, Italy
| | - Francesco Giuseppe De Rosa
- Department of Medical Sciences, University of Turin, Infectious Diseases, City of Health and Sciences, Turin, Italy
| | - Pierluigi Viale
- Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
| | - Mario Tumbarello
- Institute of Infectious Diseases, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy
| | - Carlo Tascini
- First division of Infectious Diseases, Cotugno Hospital, AORN dei Colli, Naples, Italy
| | - Claudio Viscoli
- Infectious Diseases Unit, Ospedale Policlinico San Martino - IRCCS per l'Oncologia, Italy; Department of Health Sciences, University of Genoa, Genoa, Italy
| | - Mario Venditti
- Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I, Viale dell'Università 37, 00161 Rome, Italy.
| |
Collapse
|
12
|
Bardellini E, Amadori F, Conti G, Veneri F, Majorana A. Effectiveness of a spray containing 1% malic acid in patients with xerostomia induced by graft-versus-host disease. Med Oral Patol Oral Cir Bucal 2019; 24:e190-e194. [PMID: 30818311 PMCID: PMC6441605 DOI: 10.4317/medoral.22699] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2018] [Accepted: 01/09/2019] [Indexed: 12/17/2022] Open
Abstract
Background To evaluate the clinical effectiveness of a topical sialogogue spray (malic acid, 1%) in the treatment of xerostomia in patients with chronic Graft versus Host Disease (cGVHD). Material and Methods This study was designed as a randomized double-blind clinical study. Twenty-eight patients with cGVHD suffering from xerostomia were divided into 2 groups: the first group (14 patients) received a topical sialagogue spray containing malic acid 1% (SalivAktive®) whereas the second group (14 patients) received a placebo. Both groups received treatment for 2 weeks. Dry Mouth Questionnaire (DMQ) scores and unstimulated salivary flows rate were collected before and after treatment. Results DMQ scores increased significantly from 1.3 ± 0.4 to 3.5 ± 0.4 points (p <0.05) after two weeks of treatment with malic acid, whereas in the control group DMQ scores increased from 1.2 ± 0.7 points to 1.4 ± 0.6 (p >0.05). The unstimulated salivary flow rate in patients treated with malic acid increased significantly from 0.15 ± 0.06 mL/min to 0.24± 0.08 mL/min, while that of the patients treated with placebo went from 0.16 ± 0.07 mL/min to 0.17 ± 0.09 mL/min (p >0.05). Conclusions Malic acid 1% spray can be considered effective in the treatment of GVHD induced xerostomia. Key words:Xerostomia, malic acid, transplantation.
Collapse
Affiliation(s)
- E Bardellini
- Dental Clinic, p.le Spedali Civili n.1, 25133 Brescia,Italy,
| | | | | | | | | |
Collapse
|
13
|
Botto G, Bertaglia E, Pecora D, Rapacciuolo A, Reggiani A, Marenna B, Marini M, Ferraro A, Maglia G, Badolati S, Spotti A, Ricciardi G, Amadori F, Malacrida M, Stabile G. P5484Adherence to ESC guidelines class I was associated to better prognosis, clinical response and LV reverse remodeling in a large real-world CRT population. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.p5484] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
14
|
Ferraro A, Bertaglia E, Botto GL, Rapacciuolo A, Reggiani A, Marenna B, Marini M, Mazza A, Maglia G, Badolati S, Spotti A, Ricciardi G, Amadori F, Malacrida M, Stabile G. 184Adherence to ESC guidelines class I was associated to better prognosis, clinical response and LV reverse remodeling in a large real-world CRT population. Europace 2017. [DOI: 10.1093/ehjci/eux137.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Bardellini E, Amadori F, Schumacher RF, Foresti I, Majorana A. A new emerging oral infection: Raoultella planticola in a boy with haematological malignancy. Eur Arch Paediatr Dent 2017; 18:215-218. [PMID: 28349509 DOI: 10.1007/s40368-017-0279-7] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2016] [Accepted: 02/18/2017] [Indexed: 11/30/2022]
Abstract
BACKGROUND Oral mucositis is a common complication in pediatric cancer patients, affecting up to 80% of children. Due to neutropenia and disruption of the mucosal barrier, chemotherapy-induced oral mucositis is often complicated by super-infections. CASE REPORT A 16-years old male with stage 3 Burkitt's lymphoma developed chemotherapy induced oral mucositis grade 3 (according to WHO scale). Ulcers were quickly growing (reaching a maximum diameter of 3 cm) and became greyish in colour, resulting in dysphagia and pain. A swab of the lesions was taken and microbiological tests were performed. The sample grew for Raoultella planticola, an encapsulated Gram-negative bacterium whose full pathogenic potential still needs to be defined. TREATMENT The patient received antibiotic combination therapy with Amikacin and Ceftazidime for 8 days. Complete healing of the lesions and resolution of the symptoms were reached and he completed his antineoplastic therapy without further complications. FOLLOW-UP Twelve months after the infection, he is alive and well, with no oral complaints. CONCLUSION This is the first report of a Raoultella planticola infection in a patient with chemotherapy induced oral mucositis. This type of infection must be added to the list of organisms to be considered when caring for these patients.
Collapse
Affiliation(s)
- E Bardellini
- Department Oral Medicine and Paediatric Dentistry, Dental Clinic, University of Brescia, p.le Spedali Civili n.1, 25133, Brescia, Italy.
| | - F Amadori
- Department Oral Medicine and Paediatric Dentistry, Dental Clinic, University of Brescia, p.le Spedali Civili n.1, 25133, Brescia, Italy
| | - R F Schumacher
- Paediatric Haematology-Oncology Unit, Spedali Civili di Brescia, Brescia, Italy
| | - I Foresti
- Microbiology Department, Spedali Civili di Brescia, Brescia, Italy
| | - A Majorana
- Department Oral Medicine and Paediatric Dentistry, Dental Clinic, University of Brescia, p.le Spedali Civili n.1, 25133, Brescia, Italy
| |
Collapse
|
16
|
Conti G, Bardellini E, Amadori F. Dental radiography: Embarrassing foreign objects. Br Dent J 2016; 221:3. [DOI: 10.1038/sj.bdj.2016.471] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
17
|
Bardellini E, Amadori F, Majorana A. Oral hygiene grade and quality of life in children with chemotherapy-related oral mucositis: a randomized study on the impact of a fluoride toothpaste with salivary enzymes, essential oils, proteins and colostrum extract versus a fluoride toothpaste without menthol. Int J Dent Hyg 2016; 14:314-319. [PMID: 27160933 DOI: 10.1111/idh.12226] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/19/2016] [Indexed: 10/21/2022]
Abstract
AIM The aim of this study was to assess the impact of the use of a fluoride toothpaste (Bioxtra® , Biopharm, Milan, Italy) with salivary enzymes, essential oils, proteins and colostrum extract versus a fluoride toothpaste without menthol on the oral hygiene grade and on the quality of life (QoL) of children with oral mucositis (OM) grade 1 or 2 receiving chemotherapy for Acute Lymphoblastic Leukaemia (ALL). METHODS Patients between 6 and 14 years with OM were randomly assigned to two groups, group A (Bioxtra® toothpaste) and group B (fluoride toothpaste without menthol). The patients were instructed to brush their teeth at least twice a day using a soft toothbrush with a small head. Oral hygiene grade was assessed using the simplified oral hygiene index (OHI-s); quality of life was assessed using the short form of the Oral Health Impact Profile (OHIP-14) questionnaires. The patients were evaluated on day 1(diagnosis of OM-T0) and on day 8 (T1). Statistical analysis was performed. RESULTS A total of 64 patients were enrolled. A significant difference (P < 0.001) between the mean of the OHI-s in group A (0.9 ± 1.2) and in group B (1.5 ± 1.3) was found; the overall OHIP-14 scores were not associated with the use of one or the other toothpaste (P = 0.33). CONCLUSIONS Although the use of Bioxtra® toothpaste does not affect the QoL of children undergoing chemotherapy, it may be recommended as clinically effective in improving the oral hygiene grade.
Collapse
Affiliation(s)
- E Bardellini
- Department of Medical and Surgical Specialities, Radiological Sciences and Public Health, Dental School, University of Brescia, Brescia, Italy.
| | - F Amadori
- Department of Medical and Surgical Specialities, Radiological Sciences and Public Health, Dental School, University of Brescia, Brescia, Italy
| | - A Majorana
- Department of Medical and Surgical Specialities, Radiological Sciences and Public Health, Dental School, University of Brescia, Brescia, Italy
| |
Collapse
|
18
|
Bardellini E, Tonni I, Micheli R, Molinaro A, Amadori F, Flocchini P, Piana G, Majorana A. Occlusal traits in children with neurofibromatosis type 1. Orthod Craniofac Res 2015; 19:46-53. [PMID: 26428540 DOI: 10.1111/ocr.12108] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/04/2015] [Indexed: 11/29/2022]
Abstract
OBJECTIVES Literature is poor of data about the occlusion in children affected by neurofibromatosis type 1 (NF1). This case-control study investigated the occlusal traits in a group of children with NF1. SETTING AND SAMPLE POPULATION A hundred and fifteen children with NF1 were enrolled; non-NF1 controls were sequentially selected among subjects referred to the Pediatric Dentistry Department. MATERIAL AND METHODS All patients underwent a clinical dental examination and a panoramic radiography. The following orthodontic variables were considered: molar relationship, overjet, overbite, cross-bite, scissor bite, and crowding/spacing. RESULTS Class III molar relationship resulted significantly (p = 0.01) more common in children with NF1 than in the control group as well as the unilateral posterior cross-bite (p = 0.0017). Forty-three children with NF1 (37.3%) showed radiographic abnormalities; in one case, a plexiform neurofibroma was detected. CONCLUSIONS An early orthodontic evaluation might be planned in the management of children with NF1 to prevent or decrease the need for extensive orthodontic interventions.
Collapse
Affiliation(s)
- E Bardellini
- Department of Paediatric Dentistry, Dental School, University of Brescia, Brescia, Italy
| | - I Tonni
- Department of Paediatric Dentistry, Dental School, University of Brescia, Brescia, Italy
| | - R Micheli
- Unit of Child Neurology and Psychiatry, Spedali Civili, Brescia, Italy
| | - A Molinaro
- Unit of Child Neurology and Psychiatry, Spedali Civili, Brescia, Italy
| | - F Amadori
- Department of Paediatric Dentistry, Dental School, University of Brescia, Brescia, Italy
| | - P Flocchini
- Department of Paediatric Dentistry, Dental School, University of Brescia, Brescia, Italy
| | - G Piana
- Department of Paediatric Dentistry, Dental School, University of Bologna, Alma Mater Studiorum, Bologna, Italy
| | - A Majorana
- Department of Paediatric Dentistry, Dental School, University of Brescia, Brescia, Italy
| |
Collapse
|
19
|
Burlini D, Conti G, Amadori F, Bardellini E, De Giuli C. Management of paediatric maxillofacial fractures: conventional methods and resorbable materials. Eur J Paediatr Dent 2015; 16:24-28. [PMID: 25793949] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
AIM To compare the outcomes between the use of resorbable plates and screws and the conventional methods in children with paediatric maxillofacial fractures. STUDY DESIGN a retrospective observational study was designed reviewing the clinical records from June 2007 and June 2011. Data collected included aepidemiological data, type of treatment, outcome and satisfaction questionnaire. Descriptive statistics and bivariate analysis were performed. RESULTS A total of 1122 children (0-17 years old) were studied. Children treated by conventional methods were 912, while children treated by resorbable materials were 210. The frequency of complications during recovery was similar and no statistically significant difference was noted. The satisfaction questionnaire revealed similar percentages of satisfaction, with a high degree of satisfaction. CONCLUSION Our experience suggests that resorbable devices should be considered as a treatment option, which avoids the need of further surgery to remove metallic fixation, limits hospital spending and increases children's quality of life.
Collapse
Affiliation(s)
- D Burlini
- Department of Paediatric Maxillofacial Surgery, Spedali Civili di Brescia, Brescia, Italy
| | - G Conti
- UOC Maxillofacial Surgery and Dentistry, IRCCS Fondazione Ca Granda Ospedale Maggiore, University of Milan, Milan, Italy
| | - F Amadori
- Department of Paediatric Dentistry, Dental School, University of Brescia, Brescia, Italy
| | - E Bardellini
- Department of Paediatric Dentistry, Dental School, University of Brescia, Brescia, Italy
| | - C De Giuli
- Department of Paediatric Maxillofacial Surgery, Spedali Civili di Brescia, Brescia, Italy
| |
Collapse
|
20
|
Amadori F, Doria R, Gemignani G, Flammini S, Leonildi A, Ciancia EM, Sanguinetti M, Menichetti F. [Histoplasmosis: the multiple sides of an uncommon disease]. Infez Med 2015; 23:61-68. [PMID: 25819054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Disseminated histoplasmosis is an invasive fungal infection documented in patients with impaired cellular immunity coming from endemic areas (America, Asia, Africa). We report two cases of disseminated histoplasmosis in AIDS patients paradigmatic of the multifaceted nature of the disease, which may be an expression either of an advanced state of immunosuppression or the immune reconstitution inflammatory syndrome (IRIS).
Collapse
Affiliation(s)
- Francesco Amadori
- Unita Operativa di Malattie Infettive, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy; Unita Operativa di Anatomia Patologica Seconda, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy; Laboratorio di Microbiologia, Universita Cattolica del Sacro Cuore, Policlinico A. Gemelli, Roma, Italy
| | - Roberta Doria
- Unita Operativa di Malattie Infettive, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy; Unita Operativa di Anatomia Patologica Seconda, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy; Laboratorio di Microbiologia, Universita Cattolica del Sacro Cuore, Policlinico A. Gemelli, Roma, Italy
| | - Giulia Gemignani
- Unita Operativa di Malattie Infettive, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy; Unita Operativa di Anatomia Patologica Seconda, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy; Laboratorio di Microbiologia, Universita Cattolica del Sacro Cuore, Policlinico A. Gemelli, Roma, Italy
| | - Sarah Flammini
- Unita Operativa di Malattie Infettive, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy; Unita Operativa di Anatomia Patologica Seconda, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy; Laboratorio di Microbiologia, Universita Cattolica del Sacro Cuore, Policlinico A. Gemelli, Roma, Italy
| | - Alessandro Leonildi
- Unita Operativa di Malattie Infettive, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy; Unita Operativa di Anatomia Patologica Seconda, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy; Laboratorio di Microbiologia, Universita Cattolica del Sacro Cuore, Policlinico A. Gemelli, Roma, Italy
| | - Eugenio Mario Ciancia
- Unita Operativa di Malattie Infettive, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy; Unita Operativa di Anatomia Patologica Seconda, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy; Laboratorio di Microbiologia, Universita Cattolica del Sacro Cuore, Policlinico A. Gemelli, Roma, Italy
| | - Maurizio Sanguinetti
- Unita Operativa di Malattie Infettive, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy; Unita Operativa di Anatomia Patologica Seconda, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy; Laboratorio di Microbiologia, Universita Cattolica del Sacro Cuore, Policlinico A. Gemelli, Roma, Italy
| | - Francesco Menichetti
- Unita Operativa di Malattie Infettive, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy; Unita Operativa di Anatomia Patologica Seconda, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy; Laboratorio di Microbiologia, Universita Cattolica del Sacro Cuore, Policlinico A. Gemelli, Roma, Italy
| |
Collapse
|
21
|
Tascini C, Sbrana F, Flammini S, Tagliaferri E, Arena F, Leonildi A, Ciullo I, Amadori F, Di Paolo A, Ripoli A, Lewis R, Rossolini GM, Menichetti F. Oral gentamicin gut decontamination for prevention of KPC-producing Klebsiella pneumoniae infections: relevance of concomitant systemic antibiotic therapy. Antimicrob Agents Chemother 2014; 58:1972-6. [PMID: 24419337 PMCID: PMC4023775 DOI: 10.1128/aac.02283-13] [Citation(s) in RCA: 52] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2013] [Accepted: 01/03/2014] [Indexed: 11/20/2022] Open
Abstract
Gut colonization represents the main source for KPC-producing Klebsiella pneumoniae (KPC-Kp) epidemic dissemination. Oral gentamicin, 80 mg four times daily, was administered to 50 consecutive patients with gut colonization by gentamicin-susceptible KPC-Kp in cases of planned surgery, major medical intervention, or need for patient transfer. The overall decontamination rate was 68% (34/50). The median duration of gentamicin treatment was 9 days (interquartile range, 7 to 15 days) in decontaminated patients compared to 24 days (interquartile range, 20 to 30 days) in those with persistent colonization (P<0.001). In the six-month period of follow-up, KPC-Kp infections were documented in 5/34 (15%) successfully decontaminated patients compared to 12/16 (73%) persistent carriers (P<0.001). The decontamination rate was 96% (22/23) in patients receiving oral gentamicin only, compared to 44% (12/27) of those treated with oral gentamicin and concomitant systemic antibiotic therapy (CSAT) (P<0.001). The multivariate analysis confirmed CSAT and KPC-Kp infection as the variables associated with gut decontamination. In the follow-up period, KPC-Kp infections were documented in 2/23 (9%) of patients treated with oral gentamicin only and in 15/27 (56%) of those also receiving CSAT (P=0.003). No difference in overall death rate between different groups was documented. Gentamicin-resistant KPC-Kp strains were isolated from stools of 4/16 persistent carriers. Peak gentamicin blood levels were below 1 mg/liter in 12/14 tested patients. Oral gentamicin was shown to be potentially useful for gut decontamination and prevention of infection due to KPC-Kp, especially in patients not receiving CSAT. The risk of emergence of gentamicin-resistant KPC-Kp should be considered.
Collapse
Affiliation(s)
- Carlo Tascini
- Infectious Diseases Unit, Cisanello Hospital, Pisa, Italy
| | | | - Sarah Flammini
- Infectious Diseases Unit, Cisanello Hospital, Pisa, Italy
| | | | - Fabio Arena
- Dipartimento di Biotecnologie Mediche, Università di Siena, Siena, Italy
| | | | - Ilaria Ciullo
- Infectious Diseases Unit, Cisanello Hospital, Pisa, Italy
| | | | - Antonello Di Paolo
- Division of Pharmacology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | | | - Russell Lewis
- Infectious Diseases Unit, S'Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
| | - Gian Maria Rossolini
- Dipartimento di Biotecnologie Mediche, Università di Siena, Siena, Italy
- Dipartimento di Medicina Sperimentale e Clinica, Sezione di Medicina Critica e Medicine Specialistiche, Università di Firenze, Florence, Italy
- SOD Microbiologia e Virologia, Azienda Ospedaliera Universitaria Careggi, Florence, Italy
| | | |
Collapse
|
22
|
Burlini D, Conti G, Bardellini E, Amadori F. Rare case of desmoid-type fibromatosis of the mandibular region in a child: diagnosis and surgical management. Eur J Paediatr Dent 2013; 14:333-334. [PMID: 24313589] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
AIM Desmoid-type fibromatosis is a broad group of rare disorders that originate from musculoaponeurotic structures. They represent less than 0,1% off all tumors and the annual incidence is 2-4 cases per million, with two peaks between 6 and 15 years of age and between puberty and age 40. They are rare in the oral and maxillofacial regions. Its pathogenesis is multifactorial. The treatment is still mainly represented, both in children and adults, by surgical excision. CASE REPORT A case is reported of a 8-year- old girl with desmoid fibroma in the mandible who presented at the Department of Pediatric Dentistry with a swelling measuring 4x4 cm on the lower edge of the right mandible which had appeared a few months earlier and slowly developed. The family dentist had initially diagnosed it as an odontogenic abscess from the lower right deciduous molars, but the antibiotic therapy was unsuccessful. After x-ray examination, which showed a large osteolytic lesion, mandibular CT revealed a solid expanding mass. The child was referred to the Department of Paediatric Maxillofacial Surgery where the whole mass was surgically removed. At the 2-year follow-up no relapse was noted. CONCLUSION This case stresses the importance, especially for paediatric dentists, of further diagnostic steps if suspect lesions do not heal after conventional treatment.
Collapse
Affiliation(s)
- D Burlini
- AO Spedali Civili Brescia, Dep. Pediatric Maxillo Facial Surgery, Brescia, Italy
| | | | | | | |
Collapse
|
23
|
Bardellini E, Amadori F, Flocchini P, Conti G, Piana G, Majorana A. Oral findings in 50 children with neurofibromatosis type 1. A case control study. Eur J Paediatr Dent 2011; 12:256-260. [PMID: 22185252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
AIM The scientific literature is poor of data concerning NF1-related oral manifestations in children. The purpose of this study was to investigate the oral findings in a group of children with NF1. MATERIALS AND METHODS This study was designed as a clinical research. A total of 50 children affected by NF1 were enrolled. Non-NF1 controls were selected among subjects referred to the Paediatric Dentistry Department of the Dental Clinic at the University of Brescia, Italy. The craniofacial and all the dental examinations were carried out. The following parameters were investigated: dental caries, dental abnormalities, periodontal status, oral and perioral neurofibromas, orthodontic features, mandible and temporomandibular joint abnormalities. Statistics Unpaired Student's t test was calculated for Gaussian distributed variables; Fisher's test for non-Gaussian distributed binomial variables was used. The values inferior to p <0.05 (threshold) were considered significant for the study. RESULTS Children with NF1 showed poorer oral hygiene conditions, more frequent Class III dental malocclusions and severe alterations of the mandible and the temporal mandibular joint, if compared with the control group. CONCLUSION NF1 related-oral manifestations are evidenced also during childhood, even if some of the best known, like the neurofibromas, are not yet developed. It is important to keep a long-term follow-up to monitor the possible development of other oral lesions.
Collapse
Affiliation(s)
- E Bardellini
- University of Brescia, Dental Clinic, Brescia, Italy.
| | | | | | | | | | | |
Collapse
|